Dryocrassin ABBA (Dryocrassin) 是一种具有口服活性的、可以从Dryopteris crassirhizoma中提取的黄酮类天然产物,具有抗病毒、抗菌活性。Dryocrassin ABBA 对H5N1禽流感病毒具有抗病毒活性。Dryocrassin ABBA 能抑制金黄色葡萄球菌 vWbp 的凝固酶活性。Dryocrassin ABBA 能抑制树突状细胞的免疫刺激功能,延长同种异体皮肤移植成活率。
生物活性 | Dryocrassin ABBA (Dryocrassin) is an orally active flavonoid natural product derived fromDryopteris crassirhizoma, with antiviral and antibacterial activities[1][2]. Dryocrassin ABBA exhibits antiviral activity againstH5N1avianinfluenza virus[1]. Dryocrassin ABBA inhibits the coagulase activity ofStaphylococcus aureusvWbp[3]. Dryocrassin ABBA suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival[4]. |
IC50& Target | H5N1 avian influenza virus[1] |
体外研究 (In Vitro) | Dryocrassin ABBA (Dryocrassin) inhibits the activity ofS. aureusSrtA (sortase A) with an IC50of 24.17 μM[2].
|
体内研究 (In Vivo) | Dryocrassin ABBA (Dryocrassin) (0-33 mg/kg; i.g.; daily, 7 days from day 2 to day 8) exerts a significant dose-dependent antiviral effect in mice[1]. Dryocrassin ABBA (100 mg/kg; s.c.; every 12 h for 96 h) can reduce infection and prevent mice from contractingS. aureuspneumonia[3].
Animal Model: | SPF BALB/C female mice inoculated intra-nasally with 104.5ELD50H5N1 viruses in 100 μl saline[1] | Dosage: | 33, 18, and 12.5 mg/kg | Administration: | Oral gavage, daily, 7 days from day 2 to day 8 | Result: | Significantly reduced mortality, prolonged survival rate, and improved survival time throughout the infection period. Increased body weight and reduced lung lesions and virus loads. Significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α. |
Animal Model: | Eight-week-old C57BL/6J mice infected with 30 μL of S. aureus Newman (2 × 108CFU/10 μL) by intranasal administration[3] | Dosage: | 100 mg/kg | Administration: | Subcutaneous injection, every 12 h for 96 h | Result: | Resulted a significant increase in survival. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Dryopteridaceae
- Dryopteris crassirhizomaNakai
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : 16.67 mg/mL(20.31 mM;Need ultrasonic) 配制储备液 1 mM | 1.2183 mL | 6.0914 mL | 12.1828 mL | 5 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL | 10 mM | 0.1218 mL | 0.6091 mL | 1.2183 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1.67 mg/mL (2.03 mM); Clear solution
此方案可获得 ≥ 1.67 mg/mL (2.03 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 1.67 mg/mL (2.03 mM); Clear solution
此方案可获得 ≥ 1.67 mg/mL (2.03 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|